Our patient with HER2-negative recurrent gastric cancer received two courses of capecitabine + oxaliplatin without trastuzumab as the first-line chemotherapy, followed by three courses of RAM + PTX as the second-line chemotherapy. This evidence concerns the gene ERBB2 and gastric cancer.